Table 1.
The patient's systemic treatment history.
| Date of treatment | Therapy type | CA-125 level |
|---|---|---|
| July 2008–October 2008 | IV paclitaxel, carboplatin, IV/IP paclitaxel, cisplatin | Pre-Surgical: 1479 Pre-tx: 462 Post-tx: 106 |
| January 2009–March 2009 | Letrozole | Pre-tx: 65 Post-tx: 220 |
| March 2009–April 2009 | Liposomal doxorubicin | Pre-tx: 220 Post-tx:652 |
| May 2009–October 2010 | Gemcitabine, bevacizumab | Pre-tx: 822 Post-tx:132 |
| December 2010–January 2011 | Carboplatin | Pre-tx: 172 Post-tx:1331 |
| February 2011–September 2011 | Bevacizumab, oral metronomic cyclophosphamide | Pre-tx: 658 Post-tx: 156 |
| October 2011–May 2012 | Gemcitabine, bevacizumab | Pre-tx: 156 Post-tx: 133 |
| Treatment break | ||
| January 2013–May 2013 | Pimasertib (MEK1/2 inhibitor), voxtalisib (PI3K, mTOR inhibitor) | Pre-tx: 257 Post-tx: 147 |
| June 2013–January 2014 | Bevacizumab | Pre-tx: 130 Post-tx: 317 |
| February 2014–October 2014 | Gemcitabine, bevacizumab | Pre-tx: 317 Post-tx: 436 |
| Treatment break | ||
| April 2015–October 2016 | Paclitaxel, bevacizumab | Pre-tx: 845 Post-tx: 349 |
| October 2016–January 2017 | Leuprolide | Pre-tx: 349 Post-tx: 1100 |
| February 2017–May 2017 | Bevacizumab, topotecan | Pre-tx: 1225 Post-tx: 994 |
| June 2017-Present | Pemetrexed | Pre-tx: 994 (Most Recent) |
IV, intravenous; tx, treatment.